After reviewing data, Dr. Peter Marks, the FDA’S vaccine chief, tells reporters that “at this time, it makes sense for us to wait until we have the data from the evaluation of a third dose before taking action.” Pfizer applied for an emergency use authorization for its vaccine for children aged 6 months to 4 years. Scientists continue to research a three-shot regimen, which may ultimately be the most effective vaccine regimen for children of that age group. Currently, the dosage for children 5 and under is only one tenth of the current dose for adults. Pfizer supports the idea of a three dose booster due to the data shown by other age groups. The estimated time to submit data on the third dose is early April.
To learn more, click here.